CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma.
IMROZ and BENEFIT, randomized phase 3 trials presented at ASCO Annual Meeting, investigated the combination of isatuximab (Sarclisa, Sanofi) with bortezomib, lenalidomide and dexamethasone (VRd) as a treatment for newly diagnosed older patients. Both trials proved isatuximab-VRd was more effective than the first-line treatment option.
“[This is] additional evidence suggesting maybe we should start thinking about
